In this paper, recently published in the Journal of Neurology, Neurosurgery and Psychiatry, the authors report initial findings of an ongoing community based COVID-19 study in a large UK-wide population of people with multiple sclerosis (pwMS) which coincided with the peak of the COVID-19 outbreak in the UK. The authors show that pwMS taking immunomodulatory treatments do not have an increased risk of contracting COVID-19. Moreover they did not find individual disease-modifying therapies (DMTs) to be noticeably over-represented among pwMS with COVID-19. They concluded that, during a period with strict precautions in place to prevent the spread of COVID-19, pwMS and those taking DMTs are not at an increased risk of contracting the disease.
